Antares Therapeutics, Inc. — Form D
Antares Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2025-05-15. The offering totals $136.7M, of which $30.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2025-05-15
- Form: D
- Accession: 0002059043-25-000002
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $136.7M
- Amount sold: $30.0M
- Remaining: $106.7M
- Investors: 35
- Date of first sale: 2025-05-01
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-546316
Issuer
- Name: Antares Therapeutics, Inc.
- CIK: 0002059043
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2025
- Address: ONE WINTHROP SQUARE, SUITE 400, BOSTON, MA, 02110
- Phone: 781-288-5760
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Jeffrey Albers | Director | Boston, MA |
| Shelley Chu | Director | Lexington, MA |
| Keith Flaherty | Director | Boston, MA |
| Jean-Francois Formela | Director | Cambridge, MA |
| Adam Friedman | Director | Boston, MA |
| Menelas N Pangalos | Director | Boston, MA |
| Andrew Fedder | Executive Officer | Boston, MA |
| Adam Friedman | Executive Officer | Boston, MA |
| Brian Piper | Executive Officer | Boston, MA |
| Andrew Fedder | Director | Boston, MA |
| Brian Piper | Director | Boston, MA |
Other filings by this issuer (1)
More